News

NIH Office of Research on Women’s Health Inviting Comments To Inform the Women’s Health Consensus Conference (WHCC)

The National Institutes of Health (NIH) Office of Research on Women’s Health (ORWH) is planning a Women’s Health Consensus Conference (WHCC) in October 2021, in response to a Congressional request to address NIH research efforts related to women’s health research as well as the following specific conditions, rising maternal morbidity and mortality rates, increasing rates of chronic debilitating conditions in women, and stagnant cervical cancer survival rates. The ORWH is seeking comments and testimonies from the extramural scientific community, professional societies, and the general public regarding the topics mentioned above to assist with identifying research gaps, pitfalls in clinical practices, and obtaining real-life testimonial experiences (direct or indirect) caused by any or all of the listed public health issues.

The Women’s Health Consensus Conference (WHCC) Request for Information is open for public comment through September 15, 2021. Comments must be received by September 15, 2021, to ensure consideration. Comments received after the public comment period has closed may be considered by the Office of Research on Women’s Health.

Submissions must be sent electronically to Elizabeth Barr, Ph.D., WHCC@od.nih.gov.

FOR ADDITIONAL INFORMATION CONTACT:

Questions about this request for information should be directed to Elizabeth Barr, Ph.D., Office of Research on Women’s Health, 6707 Democracy Boulevard, Suite 400, Bethesda, MD 20817, WHCC@od.nih.gov, 301-402-7895.

Further details also available here.

Recent News

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin

07/07/2026

United Therapeutics Corporation Acquires Thymmune Therapeutics

United Therapeutics Corporation (Nasdaq: UTHR) announced it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of the

07/07/2026

Governor Spanberger Announces Virginia Ranked #1 in Nation for Customized Workforce Training

Governor Abigail Spanberger announced today that Virginia is ranked number one in the United States for customized workforce training in the 22nd annual Business Facilities Rankings Report for the fourth consecutive year. Business Facilities, a leading national publication for economic development professionals, recognized the Virginia Talent Accelerator Program for its success in delivering workforce training